AstraZeneca’s Danicopan yields promising results in ALPHA Phase 3 trial in PNH
In a significant development in the healthcare industry, AstraZeneca has released positive results from the 24-week and long-term extension (LTE) period of the pivotal ALPHA ... Read More
AstraZeneca signs $39bn deal to acquire Alexion Pharmaceuticals
In a landmark move that’s poised to shake up the world of immunology and rare disease treatments, AstraZeneca has sealed a $39 billion deal to ... Read More
Alexion discloses plan for CHAMPION-ALS clinical trial of ULTOMIRIS
Alexion Pharmaceuticals has revealed plans for initiating the CHAMPION-ALS clinical trial, a phase 3 study to evaluate ULTOMIRIS (ravulizumab) for the treatment of amyotrophic lateral ... Read More
Alexion bags Ultomiris EU approval for paroxysmal nocturnal hemoglobinuria
Ultomiris EU approval : Alexion Pharmaceuticals has secured approval from the European Commission (EC) for its C5 complement inhibitor Ultomiris (ravulizumab) for the treatment of ... Read More